Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Cancer Therapy Targeting the HER2-PI3K Pathway: Potential Impact on the Heart.

Klement GL, Goukassian D, Hlatky L, Carrozza J, Morgan JP, Yan X.

Front Pharmacol. 2012 Jun 27;3:113. doi: 10.3389/fphar.2012.00113. eCollection 2012.

2.

Anti-HER2 cancer therapy and cardiotoxicity.

Babar T, Blomberg C, Hoffner E, Yan X.

Curr Pharm Des. 2014;20(30):4911-9. Review.

PMID:
24898245
3.

Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.

Nahta R, O'Regan RM.

Clin Breast Cancer. 2010 Nov;10 Suppl 3:S72-8. doi: 10.3816/CBC.2010.s.015. Review.

PMID:
21115425
4.

Cardiotoxicity of novel HER2-targeted therapies.

Sendur MA, Aksoy S, Altundag K.

Curr Med Res Opin. 2013 Aug;29(8):1015-24. doi: 10.1185/03007995.2013.807232. Epub 2013 Jun 7. Review.

PMID:
23692263
5.

Neuregulin1 as novel therapy for heart failure.

Yan X, Morgan JP.

Curr Pharm Des. 2011;17(18):1808-17. Review.

PMID:
21631420
6.

HER2 expression and PI3K-Akt pathway alterations in gastric cancer.

Sukawa Y, Yamamoto H, Nosho K, Ito M, Igarashi H, Naito T, Mitsuhashi K, Matsunaga Y, Takahashi T, Mikami M, Adachi Y, Suzuki H, Shinomura Y.

Digestion. 2014;89(1):12-7. doi: 10.1159/000356201. Epub 2014 Jan 20. Review.

PMID:
24458107
7.

Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3K/AKT/mTOR signaling.

Grunt TW, Mariani GL.

Curr Cancer Drug Targets. 2013 Feb;13(2):188-204. Review.

PMID:
23215720
8.

Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.

Ciruelos Gil EM.

Cancer Treat Rev. 2014 Aug;40(7):862-71. doi: 10.1016/j.ctrv.2014.03.004. Epub 2014 Mar 26. Review.

PMID:
24774538
9.

Current status and future perspectives of PI3K and mTOR inhibitor as anticancer drugs in breast cancer.

Zhang X, Li XR, Zhang J.

Curr Cancer Drug Targets. 2013 Feb;13(2):175-87. Review.

PMID:
23215724
10.

Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: its potential use in the treatment of bladder cancers.

Houédé N, Pourquier P.

Pharmacol Ther. 2015 Jan;145:1-18. doi: 10.1016/j.pharmthera.2014.06.004. Epub 2014 Jun 12. Review.

11.

Cardiotoxicity profile of trastuzumab.

Ewer SM, Ewer MS.

Drug Saf. 2008;31(6):459-67. Review.

PMID:
18484781
12.

Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.

Beck JT, Ismail A, Tolomeo C.

Cancer Treat Rev. 2014 Sep;40(8):980-9. doi: 10.1016/j.ctrv.2014.06.006. Epub 2014 Jul 3. Review.

PMID:
25037117
13.

Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.

Polivka J Jr, Janku F.

Pharmacol Ther. 2014 May;142(2):164-75. doi: 10.1016/j.pharmthera.2013.12.004. Epub 2013 Dec 9. Review.

PMID:
24333502
15.

Trastuzumab containing regimens for early breast cancer.

Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, D'Amico R.

Cochrane Database Syst Rev. 2012 Apr 18;(4):CD006243. doi: 10.1002/14651858.CD006243.pub2. Review.

PMID:
22513938
16.

Trastuzumab versus lapatinib: the cardiac side of the story.

Azim H, Azim HA Jr, Escudier B.

Cancer Treat Rev. 2009 Nov;35(7):633-8. doi: 10.1016/j.ctrv.2009.06.007. Epub 2009 Jul 28. Review.

PMID:
19640652
17.

The role of trastuzumab in early stage breast cancer: current data and treatment recommendations.

Lin A, Rugo HS.

Curr Treat Options Oncol. 2007 Feb;8(1):47-60. Review.

PMID:
17660958
18.

Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients.

Ghayad SE, Cohen PA.

Recent Pat Anticancer Drug Discov. 2010 Jan;5(1):29-57. Review.

PMID:
19751211
19.

Cardiac toxicity of ErbB2-targeted therapies: what do we know?

Perez EA.

Clin Breast Cancer. 2008 Mar;8 Suppl 3:S114-20. Review.

PMID:
18777950
20.

Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies.

Rayson D, Richel D, Chia S, Jackisch C, van der Vegt S, Suter T.

Ann Oncol. 2008 Sep;19(9):1530-9. doi: 10.1093/annonc/mdn292. Epub 2008 May 13. Review.

PMID:
18480068

Supplemental Content

Support Center